Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mitochondrial interaction of fibrosis-protective 5-methoxy tryptophan enhances collagen uptake by macrophages

  • Maassen, Sjors
  • Warner, Harry
  • Ioannidis, Melina
  • Jansma, Jack
  • Markus, Hugo
  • El Aidy, Sahar
  • Chiara, María-Dolores
  • Chiara, José Luis
  • Maierhofer, Larissa
  • Weavers, Helen
  • Van Den Boogart, Geert
5-methoxy tryptophan (5-MTP) is an anti-fibrotic metabolite made by fibroblasts and epithelial cells, present in a micromolar concentrations in human blood, and is associated with the progression of fibrotic kidney disease, but the mechanism is unclear. Here, we show by microscopy and functional assays that 5-MTP influences mitochondria in human peripheral blood monocyte-derived macrophages. As a result, the mitochondrial membranes are more rigid, more branched, and are protected against oxidation. The macrophages also change their metabolism by reducing mitochondrial import of acyl-carnitines, intermediates of fatty acid metabolism, driving glucose import. Moreover, 5-MTP increases the endocytosis of collagen by macrophages, and experiments with inhibition of glucose uptake showed that this is a direct result of their altered metabolism. However, 5-MTP does not affect the macrophages following pathogenic stimulation, due to 5-MTP degradation by induced expression of indole-amine oxygenase-1 (IDO-1). Thus, 5-MTP is a fibrosis-protective metabolite that, in absence of pathogenic stimulation, promotes collagen uptake by anti-inflammatory macrophages by altering the physicochemical properties of their mitochondrial membranes., This work was supported by the the European Research Council (ERC) under the European Union’s Horizon 2020 research innovation programme [grant agreement No. 862137] to GvdB; ZonMW [project grant No. 09120011910001] to GvdB; Instituto de Salud Carlos III/ FEDER “A way to make Europe/”Investing in your future" [project No. 20/01754] to MDC, and MCIN/AEI/10.13039/501100011033 [project No. PID2020-114347RB-C31] to JLC; the Wellcome Trust and Royal Society Sir Henry Dale Fellowship to HW. The authors would like to acknowledge F. Stempels for her interpretations of the FRET/FLIM experiments and P. Grijpstra for technical support.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PCDHGC3 hypermethylation as a potential biomarker of intestinal neuroendocrine carcinomas

  • Cubiella, Tamara
  • Celada, Lucía
  • San-Juan-Guardado, Jaime
  • Rodríguez-Aguilar, Raúl
  • Suárez-Priede, Álvaro
  • Poch, María
  • Dominguez, Francisco
  • Fernández-Vega, Iván
  • Montero-Pavón, Pedro
  • Fraga, Mario F.
  • Nakatani, Yoichiro
  • Takata, So
  • Yachida, Shinichi
  • Valdés, Nuria
  • Chiara, María-Dolores
Neuroendocrine neoplasms (NENs) encompass tumors arising from neuroendocrine cells in various organs, including the gastrointestinal tract, pancreas, adrenal gland, and paraganglia. Despite advancements, accurately predicting the aggressiveness of gastroenteropancreatic (GEP) NENs based solely on pathological data remains challenging, thereby limiting optimal clinical management. Our previous research unveiled a crucial link between hypermethylation of the protocadherin PCDHGC3 gene and neuroendocrine tumors originating from the paraganglia and adrenal medulla. This epigenetic alteration was associated with increased metastatic potential and succinate dehydrogenase complex (SDH) dysfunction. Expanding upon this discovery, the current study explored PCDHGC3 gene methylation within the context of GEP-NENs in a cohort comprising 34 cases. We uncovered promoter hypermethylation of PCDHGC3 in 29% of GEP-NENs, with a significantly higher prevalence in gastrointestinal (GI) neuroendocrine carcinomas (NECs) compared with both pancreatic (Pan) NECs and neuroendocrine tumors (NETs) of GI and Pan origin. Importantly, these findings were validated in one of the largest multi-center GEP-NEN cohorts. Mechanistic analysis revealed that PCDHGC3 hypermethylation was not associated with SDH mutations or protein loss, indicating an SDH-independent epigenetic mechanism. Clinically, PCDHGC3 hypermethylation emerged as a significant prognostic factor, correlating with reduced overall survival rates in both patient cohorts. Significantly, whereas PCDHGC3 hypermethylation exhibited a strong correlation with TP53 somatic mutations, a hallmark of NEC, its predictive value surpassed that of TP53 mutations, with an area under the curve (AUC) of 0.95 (95% CI 0.83–1.0) for discriminating GI-NECs from GI-NETs, highlighting its superior predictive performance. In conclusion, our findings position PCDHGC3 methylation status as a promising molecular biomarker for effectively stratifying patients with GI-NENs. This discovery has the potential to advance patient care by enabling more precise risk assessments and tailored treatment strategies., This research was funded by Instituto de Salud Carlos III through the project PI20/01754 (co-funded by the European Regional Development Fund/European Social Fund ‘A way to make Europe’/‘Investing in your future’) and the Principado de Asturias and European Regional Development Fund through the project IDI/2021/00079. We want to particularly acknowledge the patients and the Biobank of the Principality of Asturias (BioPA) (National Registry of Biobanks B.0000827) (PT23/00077 funded by ISCIII and co-funded by the European Union) integrated in the Platform ISCIII Biobanks and Biomodels for their collaboration. LC thanks The Spanish Ministerio de Ciencia, Innovación y Universidades for a FPU predoctoral contract. TC and JS-JG thank Consejería de Ciencia, Innovación y Universidad (Principado de Asturias) for Severo-Ochoa predoctoral contracts., Peer reviewed